Product Description
CHIKV VLP (PXVX0317) is an adjuvanted VLP-based vaccine in clinical development for active immunization against chikungunya disease, which is currently being evaluated in two pivotal Phase 3 trials. (Sourced from: https://www.bavarian-nordic.com/investor/news/news.aspx?news=6805)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: Priority Review - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bavarian Nordic
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Chikungunya Fever|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EBSI-CV-317-008 | P3 |
Recruiting |
Chikungunya Fever |
2028-04-01 |
|
| EBSI-CV-317-005 | P3 |
Completed |
Chikungunya Fever |
2023-06-19 |
|
| EBSI-CV-317-004 | P3 |
Completed |
Chikungunya Fever |
2023-04-03 |
|
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | P3 |
Completed |
Healthy Volunteers |
2022-12-02 |